Aktienanalyse zu Petmed Express Inc (PETS)PETSPetmed Express Inc

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

Petmed Express Inc (PETS) is not a good buy right now due to its significantly low current price of $1.18, a very low RSI of 15.415 indicating oversold conditions, and a troubling forward P/E ratio of 16.6945 suggesting overvaluation relative to its earnings outlook. The stock has also seen a drastic year-to-date change of -64.24%, reflecting ongoing financial struggles and negative sentiment. The main risk is its declining revenue trend, with Q3 2026 revenue dropping to $40.66 million from $51.96 million in Q3 2025, indicating a concerning downward trajectory.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.